Urofollicle-stimulating hormone must only be used by a physician
experienced in the treatment of infertility.
A urofollicle-stimulating hormone can cause mild to moderate ovarian
enlargement, which may be accompanied by abdominal distension and/or abdominal
pain, which usually relieves within 2 to 3 weeks.
A urofollicle-stimulating hormone can cause severe pulmonary complications
(such as acute respiratory distress syndrome, exacerbation of asthma, etc.) and
ovarian hyperstimulation syndrome, with rare reports of death.
The urofollicle-stimulating hormone can lead to ovarian hyperstimulation
syndrome, which progresses rapidly within 24 hours to several days in severe
cases, manifested as a sharp increase in vascular permeability, resulting in
rapid accumulation of fluid in the thoracic and peritoneal cavities, including
the pericardium. Early symptoms include severe pelvic pain, weight gain, nausea,
and vomiting. Ovarian hyperstimulation syndrome can occur at the end of
treatment, and reach its peak in 7 to 10 days. Follow-up should be followed up
for at least 2 weeks after treatment with urinary follicle-stimulating hormone,
and it will automatically relieve menstrual cramps. Severe cases require drug
withdrawal and hospitalization.
Can cause multiple births, and patients should be informed before the
treatment.
The above is the relevant content of Urofollitropin Instructions. If you
also have Human chorionic gonadotropin API Supplier, Human Menopausal
Gonadotropin supplier, Urofollitropin price, Urokinase manufacturer, Hormone API
Manufacturer, and other needs, you can directly contact Kangyuan by phone. We
have many years of industry experience in R&D and production The trusted
brand choice.